RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
This article was originally published in The Pink Sheet Daily
Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.
You may also be interested in...
TOKYO - In its quest to expand into the antibody therapy area, Kyowa Hakko Kogyo signed a license contract for marketing Alnylam's respiratory syncytial virus injection drug in Japan and East Asian countries, a Kyowa Hakko spokesman confirmed June 23
Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.